ScaleWiki
Explore our comprehensive collection of scientific resources, from application notes and case studies to videos and webinars.
Share
Filter By
Cell Types
Filter by G-Rex® Models
Filter by Year
Scientific Posters
CAR T Cells, T-Cells
G-Rex100M, G-Rex100M-CS
A modular and cost-effective closed-system process for CAR-T cell manufacturing using the Sepax C-Pro and SMART G-Rex®100M-CS platforms
A modular, functionally closed process built from the Sepax C-Pro and the SMART G-Rex®100M-CS yields CAR-T products whose critical quality attributes match our validated, tech-transferred open-system benchmark. Non-invasive SMART sensor readings track Day 7 yield (open R² = 0.91; closed R² = 0.97; n = 3 runs per system).
Scientific Posters
TIL Cells
G-Rex100M
SMART G-Rex® & SensoRex™ Technology for In-line, Non-Invasive, and Real-Time Monitoring of TIL Expansion
SMART G-Rex® technology enabled sampling-free tracking of TIL expansion, generating growth curves that reflect both cell growth kinetics and culture quality throughout manufacturing. In the pre-REP, a target of 142 ± 0.5 MHz identified cultures ready for an early harvest yielding 300 to 500 × 10⁶ TIL.
Publications
Other
Potency Assurance for Cellular and Gene Therapy Products; Guidance for Industry
This final guidance provides recommendations for developing a science- and risk-based strategy to assure the potency of cellular and gene therapy (CGT) products, and supersedes the January 2011 guidance on potency tests for CGT products. It covers quality risk management, product and process understanding, manufacturing process design, control strategy, and potency assays and acceptance criteria. G-Rex® is not referenced in this document.
Scientific Posters
CAR T Cells, T-Cells
G-Rex100M, G-Rex6M – 5cm²
SMART G-Rex® for Non-Invasive Monitoring of CAR-T Cell Expansion and Harvest Timing
Scientific poster from CTMC (Houston, TX) and ScaleReady presented at SITC 2026: CAR-T cultures from two healthy donors and two tumor patients (two activation methods, six cultures) were expanded in SMART G-Rex®100M bioreactors, with G-Rex®6M surrogate wells as references, and monitored non-invasively with the SMART Growth Index (SGI) on the SensoRex™ reader. SGI tracked expansion kinetics, growth-phase transitions and activation method-dependent differences, and an SGI of about 6–8 aligned with the target harvest-density window (1.25–2.5 × 10⁷ TVC/cm²), supporting further evaluation of SGI to inform harvest timing.
Scientific Posters
CAR T Cells, T-Cells
G-Rex® bioreactors as scale-up enablers in an integrated allogeneic anti-CD19 TCRαβ-KO CAR-T manufacturing platform
Scientific poster from GENYO (Granada, Spain) on the CERTERA project: a GMP-ready, end-to-end platform for universal anti-CD19 TCRαβ-KO CAR-T cells that combines CliniMACS Prodigy selection, MaxCyte GTx CRISPR/Cas9 TRAC knockout, G-Rex® expansion and GatheRex harvest. At production scale, G-Rex® delivered about 22× higher yields than Prodigy expansion while preserving memory phenotype and cytolytic function.
Publications
TCR T Cells
G-Rex500M
T cell receptor gene therapy targeting KRAS G12V for advanced pancreatic cancer in a single-arm phase 1/2 clinical trial [High Res Image]
High-resolution graphical abstract of the KRAS G12V TCR-T trial. It traces PBMC isolation, lentiviral TCR transduction, rapid expansion in a G-Rex® 500M vessel, and infusion after lymphodepletion. Outcomes shown: low-grade CRS, one complete response, and anti-TCR antibody driving rejection.
Publications
CAR T Cells, CD34 Cells, NKT Cells
G-Rex6M – 10cm²
Overcoming ovarian cancer resistance and evasion to CAR-T cell therapy by harnessing allogeneic CAR-NKT cells
Allogeneic MSLN CAR-NKT cells were generated from cord blood CD34+ HSPCs. They outperformed conventional CAR-T cells in ovarian cancer, homed to tumors, modulated the microenvironment, minimized cytokine release syndrome and GvHD, and resisted allorejection. Expansion used G-Rex® 6M well plates.
Publications
TCR T Cells
G-Rex500M
T cell receptor gene therapy targeting KRAS G12V for advanced pancreatic cancer in a single-arm phase 1/2 clinical trial
Single-arm phase 1/2 trial NCT04146298 treated five recurrent pancreatic cancer patients with autologous T cells engineered with an HLA-A*11:01-restricted KRAS G12V TCR; three had repeat infusions. Products were rapidly expanded in G-Rex® 500 flasks and rested in G-Rex® 24-well plates (Wilson Wolf).
